[{"address1": "88 Sidney Street", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "617 649 8600", "website": "https://www.agios.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 383, "companyOfficers": [{"maxAge": 1, "name": "Mr. Brian M. Goff M.B.A.", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 1458975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cecilia  Jones", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 751482, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James William Burns", "age": 45, "title": "Corporate Secretary & Chief Legal Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 1019942, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sarah  Gheuens M.D., Ph.D.", "age": 43, "title": "Chief Medical Officer and Head of Research & Development", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 1247567, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tsveta  Milanova", "age": 46, "title": "Chief Commercial Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 939048, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lewis Clayton Cantley Ph.D.", "age": 74, "title": "Founder", "yearBorn": 1949, "fiscalYear": 2023, "totalPay": 50000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.", "age": 77, "title": "Founder", "yearBorn": 1946, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Craig B. Thompson M.D.", "age": 70, "title": "Founder", "yearBorn": 1953, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shin-San  Su Ph.D.", "age": 67, "title": "Founder", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. T. J. Washburn", "age": 41, "title": "VP, Controller & Principal Accounting Officer", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 3, "compensationRisk": 4, "shareHolderRightsRisk": 7, "overallRisk": 5, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 44.14, "open": 44.26, "dayLow": 43.93, "dayHigh": 46.1899, "regularMarketPreviousClose": 44.14, "regularMarketOpen": 44.26, "regularMarketDayLow": 43.93, "regularMarketDayHigh": 46.1899, "beta": 0.746, "forwardPE": -7.4468083, "volume": 550761, "regularMarketVolume": 550761, "averageVolume": 478860, "averageVolume10days": 442170, "averageDailyVolume10Day": 442170, "marketCap": 2588636160, "fiftyTwoWeekLow": 19.8, "fiftyTwoWeekHigh": 53.29, "priceToSalesTrailing12Months": 82.68818, "fiftyDayAverage": 44.5758, "twoHundredDayAverage": 36.78075, "currency": "USD", "enterpriseValue": 2083365376, "floatShares": 50369195, "sharesOutstanding": 56893100, "sharesShort": 3275023, "sharesShortPriorMonth": 2903126, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.057600003, "heldPercentInsiders": 0.01551, "heldPercentInstitutions": 1.0412899, "shortRatio": 6.09, "shortPercentOfFloat": 0.0584, "impliedSharesOutstanding": 57466000, "bookValue": 11.613, "priceToBook": 3.9180229, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -364931008, "trailingEps": -6.5, "forwardEps": -6.11, "pegRatio": -0.63, "enterpriseToRevenue": 66.548, "enterpriseToEbitda": -5.22, "52WeekChange": 1.1708016, "SandP52WeekChange": 0.39070773, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AGIO", "underlyingSymbol": "AGIO", "shortName": "Agios Pharmaceuticals, Inc.", "longName": "Agios Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1374672600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "52f076ec-0de6-382e-b01b-3ddfa165dcb4", "messageBoardId": "finmb_46539787", "gmtOffSetMilliseconds": -14400000, "currentPrice": 45.5, "targetHighPrice": 57.0, "targetLowPrice": 51.0, "targetMeanPrice": 54.71, "targetMedianPrice": 56.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 569891968, "totalCashPerShare": 10.017, "ebitda": -399096000, "totalDebt": 64620000, "quickRatio": 9.158, "currentRatio": 10.092, "totalRevenue": 31306000, "debtToEquity": 9.783, "revenuePerShare": 0.557, "returnOnAssets": -0.27247998, "returnOnEquity": -0.44922, "freeCashflow": -223510368, "operatingCashflow": -306587008, "revenueGrowth": 0.284, "operatingMargins": -12.28288, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-21"}]